InMed Pharmaceuticals

InMed Pharmaceuticals EBIT Margin

The EBIT Margin (Operating Margin) of InMed Pharmaceuticals (INM) as of Nov 3, 2026 is -160.20 %. In the previous year, EBIT Margin (Operating Margin) was -176.92 % — a change of -9.45% (higher).

EBIT Margin

-160.20 %

YoY

-9.45%

Last updated:

EBIT Margin (Operating Margin) of InMed Pharmaceuticals is 2025 -160.20 % . EBIT Margin (Operating Margin) of InMed Pharmaceuticals was 2024 -176.92 % . It decreases by -9.45% higher compared to the previous year.

For InMed Pharmaceuticals, the operating (EBIT) margin of -160.2% is up versus -1,000.0% a few years ago.

The InMed Pharmaceuticals EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2008
-1.94 USD
Jan 1, 2009
-4.47 USD
Jan 1, 2010
-5.25 USD
Jan 1, 2011
-10.00 USD
Jan 1, 2022
-1,246.79 USD
Jan 1, 2023
-202.42 USD
Jan 1, 2024
-176.92 USD
Jan 1, 2025
-160.20 USD
The InMed Pharmaceuticals EBIT Margin history
YEAREBIT MarginYoY
-160.20 %-9.45%
-176.92 %-12.59%
-202.42 %-83.77%
-1,246.79 %+12,367.89%
-10.00 %+90.48%
-5.25 %+17.43%
-4.47 %+130.86%
-1.94 %+41.17%
-1.37 %+220.49%
-0.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

InMed Pharmaceuticals Stock analysis

What does InMed Pharmaceuticals do? InMed Pharmaceuticals Inc is a biopharmaceutical company based in Vancouver, Canada, listed on the stock exchange in June 2001. The firm operates through two main segments: InMed Pharmaceuticals and BayMedica. The InMed segment focuses on the research and development of prescription-based cannabinoid products, specifically targeting diseases with high unmet medical needs. Key candidates include INM-755, a topical skin cream for Epidermolysis Bullosa, and INM-088 for glaucoma treatment. The BayMedica segment develops proprietary manufacturing technologies to produce rare cannabinoids for the health and wellness industry. The company leverages its expertise in rare cannabinoids and analogs to address significant therapeutic gaps. InMed Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InMed Pharmaceuticals stock

EBIT Margin (Operating Margin) of InMed Pharmaceuticals is -160.20 % in 2025.

EBIT Margin (Operating Margin) of InMed Pharmaceuticals changed from -176.92 % to -160.20 %, representing a -9.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) InMed Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s InMed Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — InMed Pharmaceuticals

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — InMed Pharmaceuticals